138 related articles for article (PubMed ID: 8090332)
1. Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism.
Joffe P; Ladefoged SD; Cintin C; Jensen LT; Hyldstrup L
Nephrol Dial Transplant; 1994; 9(5):524-31. PubMed ID: 8090332
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 1 alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis.
Joffe P; Cintin C; Ladefoged SD; Rasmussen SN
Clin Nephrol; 1994 Jun; 41(6):364-9. PubMed ID: 8076440
[TBL] [Abstract][Full Text] [Related]
4. Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis.
Papapoulos SE; vd Berg H; Frölich M; Valentijn RM
Nephrol Dial Transplant; 1988; 3(5):647-50. PubMed ID: 3146722
[TBL] [Abstract][Full Text] [Related]
5. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
Shiraki M; Orimo H; Ito H; Akiguchi I; Nakao J; Takahashi R; Ishizuka S
Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014
[TBL] [Abstract][Full Text] [Related]
8. [Acute response of serum PTH and bone markers after injection of 1alpha,25 (OH)2D3 and 22-oxacalcitrol in hemodialysis patient].
Shimizu G; Mitani S; Matsumoto S; Kawakami A; Nozaki K; Naka H; Imanishi Y; Miki T; Inaba M; Nishizawa Y
Clin Calcium; 2005 Sep; 15 Suppl 1():148-51; discussion 151. PubMed ID: 16272648
[TBL] [Abstract][Full Text] [Related]
9. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
Djukanović L; Pejanović S; Dragojlović Z; Stosović M
Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man.
Gallacher SJ; Cowan RA; Fraser WD; Logue FC; Jenkins A; Boyle IT
Eur J Endocrinol; 1994 Feb; 130(2):141-5. PubMed ID: 8130888
[TBL] [Abstract][Full Text] [Related]
11. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
Brandi L; Egfjord M; Olgaard K
Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
[TBL] [Abstract][Full Text] [Related]
12. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-calcium hemodialysate on bone metabolism.
Saisu T; Wakabayashi Y; Yamada K; Shigematsu T; Goto S; Nishimura M; Miura Y; Nakano H; Moriya H
J Bone Miner Metab; 2000; 18(2):57-62. PubMed ID: 10701159
[TBL] [Abstract][Full Text] [Related]
15. Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.
Coen G; Mazzaferro S; Ballanti P; Bonucci E; Bondatti F; Manni M; Pasquali M; Perruzza I; Sardella D; Spurio A
Am J Nephrol; 1992; 12(4):246-51. PubMed ID: 1481872
[TBL] [Abstract][Full Text] [Related]
16. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
17. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
18. Evidence for acute inhibitory effects in vivo of 1 alpha-hydroxycholecalciferol on parathyroid hormone secretion in rats.
Kugai N; Koide Y; Kimura S; Yamashita K; Ogata E
Endocrinology; 1981 Oct; 109(4):1078-83. PubMed ID: 6269831
[TBL] [Abstract][Full Text] [Related]
19. An acute intake of phosphate increases parathyroid hormone secretion and inhibits bone formation in young women.
Kärkkäinen M; Lamberg-Allardt C
J Bone Miner Res; 1996 Dec; 11(12):1905-12. PubMed ID: 8970892
[TBL] [Abstract][Full Text] [Related]
20. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
